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Methods: Thirty cognitively unimpaired individuals aged 65 years or older with at least
10,000 hours of practice in mindfulness meditation (MM) and loving-kindness and compassion
meditation (LKCM) are selected. The outcomes are the neuroimaging brain correlates of MM
and LKCM and the assessments of long-term meditation practices on behavioral, neural, and bio-
logical measures as compared to nonmeditator older controls from the Age-Well randomized
controlled trial.
Results: Recruitment and data collection began in late 2016 and will be completed by late 2019.
Discussion: Results are expected to foster the understanding of the effects of meditation expertise on
aging and of the mechanisms of action underlying the meditation intervention in the Age-Well ran-
domized controlled trial. These finding will contribute to the design of meditation-based prevention
randomized controlled trials for the aged population and to the exploration of the possible long-time
developmental trajectory of meditation training.
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There is a recent interest for using meditation practice to
improve mental health and well-being in the aging popula-
tion and reduce risks for Alzheimer’s disease (AD) [1–5],
yet there is still a paucity of evidence supporting this
hypothesis. We are currently exploring this hypothesis in
the Medit-Ageing research project, which is funded by the
European Commission under the call PHC22-2015 of the
Horizon 2020 research and innovation program (grant agree-
ment No 667696; public name: Silver Sante Study; www.
silversantestudy.eu). This project includes 10 partners from
six European countries (Belgium, France, Germany, Spain,
Switzerland, and United Kingdom). It aims at assessing
the impact of meditation practice on mental health and
well-being in aging populations. Medit-Ageing includes
two independent randomized controlled trials (RCTs)
sponsored by Inserm, that is, the Subjective Cognitive
Decline-Well (SCD-Well) RCT (Marchant et al., 2018)
and the Age-Well RCT (Poisnel et al., 2018), as well asFig. 1. (A)Meditation states: Hypothetical model of the core mental processes cult
Both states are thought to enhance cognitive control and positive emotions, mindf
tation the latter (see arrows). Through these mechanisms, both practices are expec
regulation and more broadly, on mental health and well-being in aging. The Age-W
states in expert meditators using resting-state fMRI (RS-fMRI) functional connect
will be used to assess the specific contribution of each practice in the meditation in
(B) Meditation trait: Meditation expertise (i.e., trait) will be assessed by comparing
well-being. The outcomes include structural and functional brain integrity using str
sures (cognition, lifestyle, well-being, mindfulness, psychoaffective factors, and p
polysomnography, and somnoart), and neuroimaging measures (FDG and florbetaone cross-sectional study, that is, the Age-Well observational
study. The aim of this article is to present the design, hypoth-
eses, and progress of the Age-Well observational cross-
sectional study. This later complements the Age-Well RCT
by investigating a group of older expert long-term medita-
tors.
More specifically, the Age-Well observational study’s
first aim is to identify the brain signatures of specific medi-
tation practices. Indeed, the Age-Well RCT includes an 18-
month original secular program of meditation training to
both mindfulness meditation (MM) and loving-kindness
and compassion meditation (LKCM). However, the Age-
Well RCT cannot parcel out the specific contribution of
each meditation practice: its 18-month postintervention visit
characterizes only the combined effect of MM and LKCM
on mental health and well-being in the aging population.
The Age-Well observational cross-sectional study will allow
to highlight brain changes specifically associated with each
of these meditation states (i.e., MM vs LKCM; Fig. 1A) us-
ing functional magnetic resonance imaging (fMRI) dataivated during mindfulness and compassion and loving-kindness meditations.
ulness meditation enhancing particularly the former, and compassion medi-
ted to have a positive impact on emotional balance, well-being, and emotion
ell observational study aims to characterize the neural correlates of these two
ivity measures, and a neuroimaging affective paradigm. The neural markers
tervention implemented in the Age-Well clinical study (Poisnel et al. 2018).
expert and novice meditators on a variety of measures sensitive to aging and
uctural and functional MRI measures sensitive to aging and behavioral mea-
rosocialness), blood-based biological measures, sleep measures (actigraphy,
pir-PET, resting-state EEG, auditory ERP).
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states at rest (resting-state fMRI [RS-fMRI]) as well as dur-
ing and after witnessing others’ suffering in emotional video
clips, and to assess their relative regulatory effects on cogni-
tive control and emotions.
The second aim of the Age-Well observational study is to
obtain novel markers of meditation expertise (i.e., medita-
tion trait, Fig. 1B) in healthy older meditation expert partic-
ipants. Indeed, largely due to the novelty of this research,
most of our knowledge on the expected effects of meditation
practice on mental health and well-being in aging is
currently based on the existing literature on younger medita-
tors. Further knowledge is needed in older expert meditators
to refine the hypotheses and effect size calculation of future
meditation-based intervention studies in older adults. The
Age-Well observational study will collect, in the same group
of older expert meditators, detailed cognitive, behavioral,
biological, neuroimaging, and sleep measures of mental
health and well-being. The findings could then be used to
refine the predictions and interpretations of the results ob-
tained in the meditation novices of the Age-Well RCT
(where the same measures are collected) and also to deter-
mine the most sensitive measures to meditation practice in
older populations for future studies. More broadly, these
markers will inform the collective effort to improve instru-
ments and assessment methods to characterize prevention
studies in the field of aging and AD [6].
More specifically regarding the first aim of investigating
MM and LKCM (Fig. 1A), MM can be conceptualized as a
state of vigilant awareness of one’s own thoughts, actions,
emotions, and motivations [7,8]. The practitioner learns to
intentionally pay attention to his or her internal or external
experiences in the present moment, without making any
value judgment. The happy mental states (mental calm) or
unhappy mental states (ruminations and destructive
emotions) are observed without identifying with or being
absorbed by these experiences. The present moment is
lived in a more open and flexible way and is less
dominated by mental conditioning, which itself is
considered as a source of suffering [8–10]. Accumulating
clinical, behavioral, and neuroimaging evidence indicates
that the sustained practice of MM improves cognition in
young adults, mainly in the domains of attention, meta-
cognition, and memory [8], which are cognitive processes
particularly sensitive to aging and AD [3,4,8]. Eight-week
mindfulness-based psychotherapies are effective especially
for stress management and the prevention of relapse into
depression [11–13] and could also influence cardiovascular
risk factors [14]. Training in MM, ranging from 8 weeks
to 3 months, specifically impacts brain networks associated
with attention, memory, and meta-cognition, in particular,
the frontoparietal attention networks, the salience network
(insula and anterior cingulate cortex [ACC]), and more
broadly the frontopolar cortex [15,16]. Complementing
MM, the practice of LKCM aims to orient one’s attention
toward others by cultivating feelings of benevolence andkindness and to increase the motivation to help alleviating
others’ suffering (i.e., compassion) and to help increasing
others’ well-being (i.e., loving-kindness) [17,18]. Before
developing these prosocial attitudes, compassion-
meditation-based interventions often start by nurturing a
relationship of greater benevolence toward oneself, for
instance by addressing emotions such as shame, self-
criticism, or anger with more acceptation and kindness
[17,18]. Even if the role of cognitive processes in LKCM
is still debated [19,20], these processes should include
empathy, theory of mind, reappraisal, prosocial motivation,
and the self-generation of positive affect [18,21–23].
Recent evidence suggests that LKCM could also
downregulate stress, depression, and cardiovascular risk
factors [24,25]. Moreover, neuroimaging evidence shows
that empathy, mentalizing, and attention reorienting
differentially predict altruistic decision-making [26] and
that the state of LKCM modulates one’s response to human
suffering by enhancing the responses of empathy-related
brain regions, such as the insula, as well as by augmenting
activity in brain regions associated with positive affect and
affiliation, such as the striatum and the medial orbitofrontal
cortex [27–29]. A recent longitudinal study comparing
within the same participants the effect of a 3-month
attention-based meditation training with a 3-month
compassion-related meditation training found differential
training-related anatomical changes in attention and
emotion regulation-related brain areas, the former inducing
cortical thickness changes in prefrontal regions, whereas
the latter inducing cortical thickness changes in frontoinsu-
lar regions [16]. Based on this emerging literature in young
adults, we hypothesize that these two styles of meditation
will be engaging common but also distinct cognitive and
emotional processes as summarized in Fig. 1A, which
should be correlated to partly overlapping and partly specific
neural correlates in frontoparietal and limbic networks. We
hypothesize that RS-fMRI data collected during the self-
generation of these meditation states will be correlated
with changes in spontaneous functional connectivity in these
attention and affective brain areas. We also hypothesize that
the two practices will affect the processing of others’
suffering as well as the recovery from emotional challenges
as measured by fMRI during and after witnessing others’
suffering in emotional video clips. More specifically, we pre-
dict that meditators reporting either enhanced empathy and/
or positive affective experiences and/or mentalizing strategy
during LKCM will exhibit enhanced brain activations in the
core neural networks commonly activated during empathy
(e.g., anterior insula), positive affects or affiliation (e.g.,
medial orbitofrontal cortex and striatum), or theory of
mind (e.g., temporoparietal junction). We also predict that
the duration of neural activation patterns associated with
threat perception (amygdala, thalamus, insula, dorsal
ACC) in the rest period following the videos will be reduced
particularly during MM and LKCM compared to the control
condition without meditation instructions [30]. These brain
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tions, will be used as neural signatures of these meditation
states. They will allow notably to weight the relative contri-
bution of each meditation practice in the changes observed
in the novices of the Age-Well RCT.
The second aim of the Age-Well observational study is to
characterize the effects of meditation expertise on the same
behavioral, neuroimaging, sleep, and biological measures as
the ones collected in the Age-Well RCT (Fig. 1B). Overall,
we hypothesize that meditation expertise will be associated
with increases in positive emotions and cognitive control
measures compared to nonmeditator older controls. These
increases in turn are expected to be associated with positive
effects on markers of health, cognitive function, and well-
being in aging. One measure of particular importance will
be the primary outcomes of the Age-Well RCT, which mea-
sure structural and functional neuroimagingmarkers of brain
integrity. Based on our pilot study [31], we predict that medi-
tation expertise will be associated with greater volume and
perfusion in the ACC and insula compared to nonmeditator
older controls.2. Methods/design
2.1. Clinical trial setting and design
The Age-Well observational, cross-sectional study is a
monocentric trial with 30 autonomous and motivated cogni-
tively normal older expert meditators aged 65 years.
The clinical trial protocol (EudraCT: 2016-002441-36;
IDRCB: 2016-A01767-44, ClinicalTrials.gov Identifier:
NCT02977819) adheres to Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) guidelines for
clinical trial protocols [32].
2.2. Participant recruitment and prescreening
Expert meditators should have extensive practices in two
families of Buddhist meditations: MM (i.e., Samatha/Vipas-
sana, or Zazen [Zen], Shikantaza [Zen], one-pointed focused
attention, or Mahamudra/Dzogchen in Tibetan Buddhism),
and LKCM (e.g., Tonglen meditation, practices on the
Four Immeasurables [e.g. metta meditation], meditation on
Bodhicitta). Expert meditators are recruited in Europe
through flyers, advertisement in Buddhist magazine,
e-mails, and presentations in Buddhist meditation retreat
centers. Interested practitioners are invited to fill in a ques-
tionnaire to prescreen the individuals who fit with the main
eligibility criteria.
2.3. Participant selection: Eligibility criteria and
screening visit (V0)
Motivated participants corresponding to the target popu-
lation are invited to the screening visit (V0) where complete
written and oral information is provided and an informed
consent is signed. The screening visit comprises a medicalinterview and a cognitive assessment with a neuropsycholo-
gist where the diagnostic battery tests are performed (see
Poisnel et al. 2018 for details). Inclusion and exclusion
criteria for participants in the Age-Well observational study
are detailed in Table 1. Briefly, participants are cognitively
normal older individuals (aged  65 years), with no major
neurological or psychiatric disorder, with an intensive and
regular practice of meditation (i.e., at least 10,000 hours of
formal meditation in their life including at least 6 cumulative
months spent in retreat [at least 8 hours per day of formal
meditation] and a regular daily meditation practice, at least
6 days a week of at least 45 minutes of meditation, profi-
ciency in MM and LKCM). The medical doctor verifies
these criteria and performs a general health screening
comprising medical history, drug therapies, measurement
of height and weight, hip and waist circumferences, and
sitting blood pressure.
2.4. Measures collected at V1
Fig. 1A describes the measures collected only for experts,
and Fig. 1B describes the measures collected for experts and
for novices who participate in the Age-Well RCT (Poisnel
et al. 2018). The former ones are used to assess meditative
states, the latter ones to assess meditation-related traits,
such as meditation expertise. The detailed biological, behav-
ioral, neuroimaging, and sleep measures collected at the V1
visit are listed in Poisnel et al. 2018. Briefly, behavioral mea-
sures include a series of neuropsychological tests, scales,
and questionnaires particularly sensitive to aging and AD
(e.g., assessing episodic memory, attention, and executive
functions) and/or meditation practices (e.g., assessing
well-being, mindfulness and meta-cognition, emotion regu-
lation, altruism, and prosociality), or to assess different as-
pects of sleep quality, lifestyle, and quality of life.
Neuroimaging measures include a series of structural and
functional (resting-state and task-related) MRI scans,
FDG- and florbetapir-PET scans, and resting-state EEG
and auditory event-related potential recording. Objective
measures of sleep include actigraphy, somnoart, and poly-
somnography, and biological measures are obtained from
blood sampling. All assessment procedures were discussed
and audited by experienced and skilled study staff to ensure
the standardization of the procedures.
2.5. Blinding
As the expert meditators’ data were collected between the
three successive cohorts spaced about 6 months apart of the
Age-Well Clinical RCT, the interviewers, psychometrists,
and outcome assessors were not blind to the group condition.
2.6. Outcome measures
The outcomes of the Age-Well observational study are
listed in Table 2. As depicted in Fig. 1A, the first objective
is to measure the differential engagement of brain areas
Table 1
Inclusion and exclusion criteria for the Age-Well observational study
Inclusion criteria Exclusion criteria
Age  65 years Safety concerns in relation to MR scanning (claustrophobia, ferromagnetic
object) or PET scanning (Blood sampling to check hepatic and renal
functions are performed before the PET scans; known hypersensibility to
Amyvid or Glucotep)
Autonomous Presence of a major neurological or psychiatric disorder (including an
addiction to alcohol or drugs)
Living at home History of cerebral disease (vascular, degenerative, physical malformation,
tumor, or head trauma with loss of consciousness for more than an hour)
Educational level  7 years (from the preparatory course—first grade—
included)
Presence of a chronic disease or acute unstable illness (respiratory,
cardiovascular, digestive, renal, metabolic, hematologic, endocrine, or
infectious)
Registered to the social security system Current or recent medication that may interfere with cognitive functioning
(psychotropic, antihistaminic with anticholinergic action, anti-Parkinson’s,
benzodiazepines, steroidal antiinflammatory long-term treatment,
antiepileptic, or analgesic drugs), the interfering nature of the different
treatments being at the discretion of the investigating doctor
Motivated to effectively participate in the project and signing the informed
consent form
Being under legal guardianship or incapacitation
Performance within the normal range on standardized cognitive tests
according to agreed study-specific standards (age, sex, and education level
when available)
Participation to another biomedical research protocol including the injection
of radiopharmaceuticals
10,000 hours of formal meditation in their life including at least 6 cumulative
months spent in retreat
Physical or behavioral inabilities to perform the follow-up visits as planned in
the study protocol
A regular daily meditation practice, at least 6 days a week of at least
45 minutes of meditation
Extensive experience in mindfulness meditation [i.e., mindfulness, Samatha/
Vipassana, Zazen (Zen), Shikantaza (Zen), focused attention, Mahamudra/
Dzogchen] and loving-kindness and compassion meditation (i.e., Tonglen
practice, 4 incommensurables qualities practice [metta/karuna], Bodhicitta
meditation)
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ing two forms of meditation (MM and LKCM) as measured
by RS-fMRI and task-related fMRI. The second objective is
to test whether behavioral, neuroimaging, biological markers
of aging, well-being, and cognition are positively affected by
meditation expertise (Fig. 1B). The endpoints will be the
mean differences in the measures cited above between the
older expert meditators and the nonmeditator older controls
from the Age-Well RCT. Of particular interest will be to
test whether meditation expertise is associated with superior
volume and perfusion activity of the anterior cingulate cortex
and the insula compared to nonmeditator older controls from
the Age-Well RCT, which will corroborate the hypothesis of
the primary outcome of the Age-Well RCT [33,34].2.7. Statistical considerations2.7.1. Sample size calculation
Studies in experienced meditators assessing compassion
meditation-related changes in fMRI brain activity showed
an effect size (calculated for the fMRI change in the insula
in response to emotional stimuli) of d 5 0.74 [35]. Our po-
wer to detect a significant group difference at a P 5 .05 a
level, 2-tailed with an n of 30 per group will thus be in the
range of 0.80.2.7.2. Volunteer characteristics
Appropriate descriptive statistics for demographic, dis-
ease history, and baseline characteristics will be presented
to compare the expert meditators with nonmeditator older
controls from the Age-Well RCT. Categorical variables
will be presented as the number and percentage of volunteers
in each category. Continuous variables will be summarized
using descriptive statistics (e.g., n, mean, standard deviation,
median, minimum, and maximum).
2.7.3. Analysis of the endpoints
Paired sample t-tests or Wilcoxon tests (for non-normally
distributed parameters) will be performed to compare the
behavioral and neuroimaging measures collected during
MM and LKCM. Two sample t-tests or Mann-Whitney tests
(for non-normally distributed parameters) will be used to
compare the other biological, neuroimaging, and behavioral
measures in the expert meditators versus the nonmeditator
older controls from the Age-Well RCT.
If the distribution of baseline confounding factors (age,
education, gender, Mini–Mental State Examination) is un-
balanced between groups, the main and sensitivity compar-
ative analyses will be performed with adjustment on those
factors. An exploratory analysis of the effect of the exposure
to meditation (number of hours of practice in life) will be
performed with available data using appropriate models.
Table 2
List of collected measures and corresponding outcomes
Measures collected at V1 Outcomes
Behavioral measures (Poisnel et al. 2018 for details):
Series of neuropsychological tests, scales, and questionnaires
particularly sensitive to aging and AD (e.g., assessing episodic memory,
attention, and executive functions) and/or meditation practices (e.g.,
assessing well-being, mindfulness and meta-cognition, emotion
regulation, altruism, and prosociality), or as they allow to assess
different aspects of sleep quality, lifestyle, and quality of life.
Composite scores and raw individual measures of cognitive performance,
well-being, mindfulness and meta-cognition, emotions, emotion
regulation, altruism, prosociality, sleep quality, lifestyle, and quality of
life of the participants. Partner perception of the participant’s well-being,
willingness to help, social interactions, and memory capacity.
Neuroimaging measures (Poisnel et al. 2018 for details):
1. Structural MRI
(a) 3D T1 and fluid-attenuated inversion recovery (FLAIR)
(b) High-resolution proton-density focused on the hippocampus
(c) Diffusion Kurtosis Imaging (DKI)
(d) Quantitative Susceptibility Mapping (QSM)
2. Functional MRI -fMRI
(a) Resting-states fMRI (at rest, mindfulness meditation [MM], and
loving-kindness and compassion meditation [LKCM])
(b) Task-related fMRI
i) The AX-CPT task [1]
ii) The SoVT-Rest task (without meditation-specific
instructions, MM, and LKCM)
3) Resting-state EEG
4) Auditory event-related potential (ERP) using the mismatch
negativity protocol [2]
5) PET scans
(a) Glucotep (FDG)-PET scan
(b) Amyvid (Florbetapir, AV45)-PET scan
- Gray and white matter volume
- White matter lesions (number and size per type and location)
- Hippocampal subfield volumes
- Fractional anisotropy and mean diffusivity
- Magnetic susceptibility index
- Brain functional connectivity
- Behavioral and brain activity measures associated with attentional
processes (alertness, inhibition, sustained attention)
- Behavioral and brain activity and connectivity changes associated
with emotions and emotional inertia
- Resting-state spontaneous oscillatory activity
- ERP measures of brain activity associated with auditory mismatch
negativity
- Resting-state brain glucose consumption
- Brain perfusion from early florbetapir-PET acquisition
- Brain amyloid load from late florbetapir-PET acquisition
Biological measures from blood (Poisnel et al. 2018 for details):
Fasting sampling performed in the morning and after one day of diet
excluding serotonin-rich food (tomatoes, avocados, pineapple, chocolate,
bananas, etc.). 18 tubes (68 mL) of blood collected at V1 and 16 tubes
(62 mL) at V3.
- Global health: blood count, glucose, cholesterol/lipid profile, urea,
creatinine, g-glutamyltransferase, glutamic oxaloacetic transaminase,
Glutamic pyruvic transaminase, brain natriuretic peptide, thyroid-
stimulating hormone
- Stress/inflammation: high-sensible C-reactive protein, cytokines,
cortisol, superoxide dismutase
- Aging/AD (telomere length, telomerase activity, b-amyloid (Ab)
1-40/42, total tau, phospho-tau, tissue plasminogen activator,
plasminogen activator inhibitor-1, brain-derived neurotrophic factor,
insulin, insulin growth factor-1, lymphocyte immunophenotyping,
repressor element 1-silencing transcription factor, neurofilament
- Mood: serotonin,
- Sex/gender: bioavailable testosterone, estradiol, sex hormone binding
globulin, dehydroepiandrosterone sulfate
- Genetic: Apolipoprotein E, Genome Wild Association Study
- Epigenetics
Objective measures of sleep:
1) 1-week wrist actigraphy recording
2) 2-nights at-home polysomnography
3) A 2D-object location task performed before and after night sleep
- Indices of mean sleep duration, sleep fragmentation and regularity of
the rest-activity cycle obtained from activity and resting state
- Multiple indices of sleep quality
- Behavioral measures of overnight memory consolidation
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wise and region-of-interest-based analyses. For fMRI data
analysis, we will be using several statistical packages:
SPM software (Wellcome Trust Centre for Neuroimaging,
London), PLS [36,37], and CONN toolbox (www.nitrc.
org/projects/conn, RRID:SCR_009550, [38]) on Matlab
(MathWorks, Natick, MA). For other statistical analyses,
we will use R statistical software [39], SAS (https://sas.com), IBM SPSS Statistics for Windows (Armonk, NY;
IBM Corp) and Statistica (StatSoft, Dell Software).2.8. Ethics and safety aspects
The Age-Well observational study was approved by the
local ethics committee (Comite de Protection des Person-
nes CPP Nord-Ouest III, Caen; trial registration number:
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The study conforms to the principles of good clinical prac-
tice. Participants give their written informed consent
before enrollment in the study. The sponsor of the clinical
trial has insurance for all participants. The disadvantages
and risk of adverse events in the present study are consid-
ered as low. Blood samples are drawn from the antecubital
vein after disinfection with alcohol swabs. There is a min-
imal risk of infection and bleeding related to the proced-
ure. There are no known side effects to MRI, but the
procedure can be uncomfortable. A thorough anamnesis
is carried out during the medical examination to account
for contraindications (metal implants, etc.). Unexpected
findings will be dealt with according to local hospital
guidelines.
2.9. Data management and monitoring
The sponsor (Inserm) has established a trial steering com-
mittee according to Good Clinic Practice guidelines with the
responsibility to provide oversight of the conduct of the trial,
advice on scientific credibility on behalf of the sponsor and
the funder, and to assess the progress of the protocol. An
external Data and Safety Monitoring Board (DSMB) inde-
pendent of the sponsor was appointed to (1) evaluate the
safety of participants included in the Age-Well trial and
(2) recommend preserving the scientific and the ethical
integrity of the study.
More details on data management and monitoring can be
found in Poisnel et al. (2018).
2.10. Study progress
From May 2016 to September 2018, 45 individuals
responded to flyers, conferences at meditation centers, in-
person request, and e-mail request. Among those, 21 partic-
ipants were interested in participating and screened (V0
visit) and 20 were included (70% men and 30% women).
The reason for noninclusion was abnormal performance in
the diagnostic battery. Recruitment will be achieved in late
2019. Electronic data entry and processing is currently
ongoing.3. Discussion
The Age-Well observational study is part of the Medit-
Ageing project, a European research initiative to foster
healthy aging and older adults’ well-being by understanding
factors that could prevent and delay age-related diseases and
disabilities. It is the first cross-sectional study to exhaus-
tively explore the relationship between meditation expertise,
aging, and well-being with a multidisciplinary, multimodal
approach that combines behavioral, neuroimaging, sleep,
and biological measures. The close association of the Age-
Well observational study with the Age-Well RCTwill enable
the identification of novel markers of meditation expertise in
healthy older meditators and the refinement of hypothesesand interpretations in the Age-Well RCT. Studying the neu-
ral correlates of MM and LKCM will enable us to better
characterize the specific contribution of two styles of medi-
tation training on cognitive control and emotion regulation.
A better understanding of the mechanisms of action of medi-
tation will facilitate sensitivity to intervention analysis and
help refine and tailor future meditation-based interventions.
Understanding these regulatory training regimes is crucial in
aging as psychoaffective factors such as stress, anxiety, and
depression, significantly contribute to reduced quality of life
and increased risk for dementia in older adults [40–42].
An important limitation of the study comes from its
cross-sectional design that prevents us from studying any
causal relationship associated with meditation practice. In
particular, it is possible that some group differences will
reflect other factors such as difference in worldview, life-
style, or diet. By collecting quantitative and qualitative
measures of many of these lifestyle factors, we will be
able to explore some of these alternative interpretations,
even if this study will not be able to disentangle whether
these factors influenced meditation practice (i.e., confound-
ing factor) or were influenced by meditation practice (i.e.,
mediation factor of meditation practice). As we collected
identical measures in the longitudinal Age-Well RCT, we
will be able to address some of these interpretative limita-
tions by identifying the expert-related effects in the Age-
Well observational study, which are overlapping, or not,
with the training-related effects from the Age-Well RCT.
From this comparison, we might be able to simulate the
possible long-time developmental trajectory of meditation
training beyond the 18 months of training used in the
Age-Well RCT. This comparison will guide future research
designs concerned with optimizing the duration of a medi-
tation training for the elderly. Another limitation comes
from the heterogeneity of the meditation traditions. In
particular, the various traditions weight somewhat differ-
ently on the relative role of MM and LKCM in the training.
However, this heterogeneity can also be viewed as a
strength. The different Buddhist traditions represented
here (Zen, Theravada, and Tibetan Buddhism) will help to
generalize any observed effect beyond particular traditions.
Post hoc analyses will explore the influence of individual
meditation practice preferences on the measures. The
extended plan will be to compare the effects on aging of
various domains of expertise such as meditation, sport, mu-
sic, and chess.
Using an innovative approach, results from the Age-Well
studies are expected to improve understanding of the mech-
anisms through which different forms of meditation may
foster healthy aging and older adults’ well-being, in addition
to preventing and delaying age-related diseases and disabil-
ities. The Age-Well observational study should help shape
and optimize future lifestyle- and meditation-based clinical
trials and facilitate the integration of meditation practice
into existing and future preventive programs and clinical in-
terventions for older people.
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1. Systematic review: We identified observational trials
by searches of clinicaltrials.gov. Search terms: Con-
dition or disease: ageing; healthy; Age: senior (ac-
cepts healthy); Study type: observational; other
terms: prevention. Two studies were identified.
2. Interpretation: The Age-Well observational study is
the first observational study to assess the specific
cognitive and affective brain correlates of two distinct
styles of meditation and the effects and mechanisms
of long-term meditation practice on behavioral, neu-
roimaging, sleep, and biological markers of mental
health and well-being in the aging population. This
study addresses whether older expert meditators have
enhanced brain and cognitive reserve, emotion regu-
lation, well-being, sleep, global health, and quality of
life compared to nonmeditator older controls.
3. Future directions: The Age-Well observational study
will contribute to the design of meditation-based
prevention randomized controlled trials and to the
exploration of the possible long-time developmental
trajectory of meditation training.References
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